SAN DIEGO, July 27, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, today announced that its major investment AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM) has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept study (POC) with its cannabidiol (CBD) and Gabapentin chewing gum product to treat restless leg syndrome (RLS) in patients.
The PK and double blind, randomized, single-center phase 2 trial will demonstrate the efficacy of AXIM's chewing gum product composed of Gabapentin and CBD on around 30 study participants to treat RLS. The CRO is conducting the trial in Israel.
"We are proud to support AXIM Biotech as the company continues to identify new clinical applications for its proprietary chewing gum product," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "Research shows that RLS may be related to abnormalities in the nervous system, and even the U.S. Department of Health and Human Services has a patent titled 'Cannabinoids as Antioxidants and Neuroprotectants.' We believe that advancements in clinical cannabinoid research may hold keys to helping people experience symptomatic relief from challenging and debilitating neurological disorders."
Restless leg syndrome (RLS), also known as Willis–Ekbom Disorder (WED), is a condition associated with nocturnal sensorimotor symptoms, or nocturnal spasms of the muscles of the lower extremities, that can result in significant sleep disruption and severe pain. RLS is a prevalent condition, affecting an estimated 3.9–14.3 % of the U.S. population. RLS can negatively affect a patient's quality of life (QoL) across several domains, such as daytime sleepiness, decreased general health, decreased immune function, stress, and mood.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s video statement, click here.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
About AXIM®
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
[email protected]
www.cmwmedia.com
View original content:http://www.prnewswire.com/news-releases/medical-marijuana-inc-major-investment-axim-biotech-enters-agreement-with-israel-based-cro-to-begin-clinical-poc-study-for-treatment-of-restless-leg-syndrome-300495170.html
SOURCE Medical Marijuana, Inc.
